Literature DB >> 3802690

Steady-state pharmacokinetics of controlled release oral morphine sulphate in healthy subjects.

J J Savarese, P D Goldenheim, G B Thomas, R F Kaiko.   

Abstract

The pharmacokinetics of oral morphine sulphate as controlled release tablets ('MS-Contin') and solution were compared at steady-state. Plasma morphine concentrations were determined over 24 hours following the last dose of each drug when given in a randomised, crossover fashion to healthy subjects. Radioimmunoassay was used, which was sensitive yet provided good specificity relative to high-performance liquid chromatography. Controlled release tablets had 86% the bioavailability of the solution. Although each dose of controlled release tablets was double that of the solution, their peak plasma concentrations were the same. Time to maximum concentration was 3 times longer for controlled release tablets with an absorption half-life twice that of the solution. Elimination of both drugs was similar and biphasic with the minor terminal portion at 10 times the half-life of the major early process. These data explain the analgesic duration of 12 hours observed in clinical studies and the lack of accumulation with morphine compared with methadone.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3802690     DOI: 10.2165/00003088-198611060-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  16 in total

1.  Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment.

Authors:  K Verebely; J Volavka; S Mulé; R Resnick
Journal:  Clin Pharmacol Ther       Date:  1975-08       Impact factor: 6.875

2.  Morphine metabolism in man.

Authors:  S F Brunk; M Delle
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

3.  Clinical pharmacokinetics of methadone.

Authors:  M I Nilsson; U Meresaar; E Anggård
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1982

4.  Sensitive and specific morphine radioimmunoassay with iodine label: pharmacokinetics of morphine in man after intravenous administration.

Authors:  R A Moore; D Baldwin; M C Allen; P J Watson; R E Bullingham; H J McQuay
Journal:  Ann Clin Biochem       Date:  1984-07       Impact factor: 2.057

5.  Controlled release morphine sulphate tablets--a study in normal volunteers.

Authors:  S T Leslie; A Rhodes; F M Black
Journal:  Br J Clin Pharmacol       Date:  1980-05       Impact factor: 4.335

Review 6.  The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone.

Authors:  B A Berkowitz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Pharmacokinetics of morphine by radioimmunoassay: the influence of immunochemical factors.

Authors:  D H Catlin
Journal:  J Pharmacol Exp Ther       Date:  1977-01       Impact factor: 4.030

Review 8.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

9.  Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers.

Authors:  M Vater; G Smith; G W Aherne; A R Aitkenhead
Journal:  Br J Anaesth       Date:  1984-08       Impact factor: 9.166

10.  Controlled-release morphine tablets. A double-blind trial in dental surgery patients.

Authors:  G W Hanks; N M Rose; G W Aherne; E M Piall; S Fairfield; T Trueman
Journal:  Br J Anaesth       Date:  1981-12       Impact factor: 9.166

View more
  6 in total

Review 1.  Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.

Authors:  P S Banerjee; J R Robinson
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Further development of a morphine hydrogel suppository.

Authors:  L Cole; C D Hanning; S Robertson; K Quinn
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

4.  The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers.

Authors:  P J Hoskin; G W Hanks; G W Aherne; D Chapman; P Littleton; J Filshie
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

5.  Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations.

Authors:  J Hasselström; J Säwe
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

6.  A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.

Authors:  Junya Sato; Rei Tanaka; Hiroshi Ishikawa; Tsutomu Suzuki; Michihiro Shino
Journal:  Support Care Cancer       Date:  2019-06-11       Impact factor: 3.359

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.